Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
April 8, 2025
Biotechnology
-
-
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
April 4, 2025
-
Nutriband Signs Partnership Agreement with Charlotte FC
April 4, 2025
-
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics
March 31, 2025
-
Dominari Holdings Investment, American Data Centers, Becomes American Bitcoin in Transformative Bitcoin Mining Deal with Hut 8
March 31, 2025
-
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
March 28, 2025
-
Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
March 28, 2025
-
Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk
March 24, 2025
-
PharmAla Contracts with Partner to Act as US Distributor
March 24, 2025
-
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases
March 24, 2025
-
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
March 21, 2025
-
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
March 20, 2025
-
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
March 20, 2025
-
MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO
March 19, 2025
-
AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test
March 18, 2025
-
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.
March 13, 2025